Neurelis is a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for epilepsy and orphan neurologic disorders. Its lead product, VALTOCO (diazepam nasal spray), was approved by the FDA in 2020 for acute treatment of seizure clusters in patients aged 6 years and older and was granted Orphan Drug Exclusivity. VALTOCO is a proprietary formulation using INTRAVAIL transmucosal absorption enhancement technology, and the FDA recognized its intranasal route as a clinically superior contribution to patient care compared with the previously approved rectal gel. Neurelis is also developing NRL-2 for intermittent use to control acute panic attacks, NRL-3 as a noninvasive acute therapy for status epilepticus, NRL-4 as a noninvasive rescue therapy for acute agitation in schizophrenia and bipolar I mania, and NRL-1049 (previously BA-1049), a preclinical ROCK inhibitor for cerebral cavernous malformations. The company has stated it will use financing to invest in VALTOCO's commercial growth, advance its internal pipeline, and potentially pursue external opportunities such as licensing. Neurelis is based in San Diego. Neurelis develops and commercializes noninvasive drug-delivery therapies for epilepsy and broader CNS indications, with a lead product VALTOCO® (diazepam nasal spray). The company intends to use its new financing to commercialize VALTOCO and to continue development and expansion of its neuroscience pipeline. VALTOCO was approved by the FDA on January 10, 2020 for acute treatment of seizure clusters in adults and pediatric patients 6 years and older. Neurelis is developing additional candidates including NRL-2 for acute panic attacks, NRL-3 for seizures progressing to status epilepticus, and NRL-4 for acute agitation in schizophrenia and bipolar I mania. The company’s technology platform includes three proprietary noninvasive delivery and stabilization technologies — Intravail®, ProTek® and Hydrogel™ — applicable to proteins, peptides, macromolecules and small molecules. Led by CEO Craig C. Chambliss and based in San Diego, CA, Neurelis recently completed a significant Series D financing. Neurelis, Inc. is a San Diego-based specialty pharmaceutical company that licenses, develops and commercializes product candidates for epilepsy and the broader central nervous system market. Its lead program is NRL-1, an intranasal diazepam being developed for pediatric, adolescent and adult patients who experience acute repetitive or cluster seizures. NRL-1 is in the final phase of clinical development and the company planned to submit an NDA in 2018. Neurelis will use newly raised funds to complete clinical trials for NRL-1, prepare the planned New Drug Application for submission to the U.S. FDA, and begin preparations for the product's commercial launch. The company is led by President and CEO Craig C. Chambliss. Neurelis is a San Diego-based specialty pharmaceutical company focused on the treatment of central nervous system disorders. Led by President and CEO Craig C. Chambliss, Neurelis is developing NRL-1, a proprietary intranasal diazepam formulation delivered via nasal spray. NRL-1 is being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control acute repetitive seizure activity (cluster seizures). The program has been granted Orphan Drug Designation by the FDA. Neurelis closed a Series A financing led by LYZZ Capital and will use the funds to advance NRL-1 through the remaining clinical work and prepare an NDA submission to the FDA.

Total raised

$264M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Aug 2021